The American Heart Association guidelines on resuscitation have recently come out. Hypothermia between 32°C and 34°C was recommended as a Class I indication in the 2010 guidelines for shockable rhythms. The resuscitation council referred to two articles that were published in NEJM in 2002 for this robust recommendation. The Targeted Temperature Management (TTM) trial that came out in 2013 had contrary findings compared with those of these previous articles. Despite the results of the TTM trial, the resuscitation council preferred to keep the recommendation level as Class I rather than lowering it (1). Although it has been retained as Class I, the recommended body temperature recommended is in the range of 32°C-36°C. This might be related to the intention of not stepping back rather than scientific concerns.
Taking a glance at pioneering articles that underpinned the 2010 guidelines for hypothermia may lead to a comprehensive insight on the issue. The first trial was a small study by Bernard et al. (2) . They conducted a quasi-randomized trial in patients who had a spontaneous return of circulation following a cardiac arrest due to ventricular fibrillation (VF). The intervention was cooling the patients at 33°C for 12 hours (h). The favoring neurological outcome was 49% in intervention group and 26% in control group (p=0.046). The second trial was by the "Hypothermia After Cardiac Arrest Group, " in which over 250 patients were enrolled, and this trial had a larger sample size than the first (3). The authors studied hypothermia defined as 32°C-34°C for 24 h in patients who had return of spontaneous circulation (ROSC) following VF. Favoring neurological outcome assessed by the Pittsburgh cerebral performance scale was reported to be 55% in the intervention group and 39% in the control group (p=0.009). The findings of these two trials have been cited for stating hypothermia as a Class I recommendation in patients who have ROSC following VF arrest.
Robust data regarding hypothermia in cardiac arrest patients has been presented by the TTM trial that came out in 2013 (4). It had been conducted in 36 intensive care units in Europe and Australia and has recruited over 900 patients. The TTM trial compared 33°C vs. 36°C that can also be defined as normothermia. The authors recruited all patients either with shockable or non-shockable rhythms except unwitnessed patients with an initial rhythm of asystole. Poor neurological outcome (Modified Rankin Scale score of 4-6) was the same in both groups (52% vs 52%, respectively) and was 54% in the hypothermia group and 52% in the control group when assessed by the Cerebral Performance Category of 3-5 (p=0.78). Despite the lack of subgroup analysis reporting the neurological outcome for shockable rhythms, mortality rates were 40.8% in the hypothermia group and 39.7% in the control group for patients who had an initial shockable rhythm.
The detailed analysis of the studies and meta-analysis on the issue are available in the current issue of the Eurasian Journal of Emergency Medicine (5) . A classical phenomenon has been posed in hypothermia trials that studies with a small sample size are prone to misleading effects of random error and chance factor. Random error indicates the effect of heterogeneity factor on the results and findings of small studies. Studies with small sample sizes might have fluctuating results and will be closer to the real values when more patients are recruited; this can be explained by the law of large numbers. The first two trials composed the basics of the recommendation in 2010 had approximately 350 patients, and the TTM trial brought out the unfavorableness of performing robust recommendations using the findings of small trials rather than waiting for more powered ones.
